Another fantastic result, that opens another dimension for Clarity's diagnostic suite.
AT: "Copper-64 has comparably low radiation doses to currently used isotopes and involves similar management of patients. However, the longer half-life of copper-64 of 12.7 hours, combined with Clarity’s proprietary position in copper-based theranostics, now sets up a foundation for a complete suite of next-generation radiodiagnostics, which could be unmatched in the radiopharmaceutical sector. The opportunity for centralised, multi-layer manufacturing and broad distribution means that every patient with access to PET imaging can potentially have optimal cancer diagnostic care, not limited by isotope half-life."
- Forums
- ASX - By Stock
- CU6
- Ann: Last patient assessment completed for SARTATE trial
CU6
clarity pharmaceuticals ltd
Add to My Watchlist
2.92%
!
$4.23

Ann: Last patient assessment completed for SARTATE trial, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.23 |
Change
0.120(2.92%) |
Mkt cap ! $1.380B |
Open | High | Low | Value | Volume |
$4.46 | $4.62 | $4.20 | $25.87M | 5.924M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 10842 | $4.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.25 | 23779 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 30590 | 4.250 |
6 | 11688 | 4.240 |
7 | 18770 | 4.230 |
9 | 24087 | 4.220 |
15 | 55579 | 4.210 |
Price($) | Vol. | No. |
---|---|---|
4.270 | 5079 | 27 |
4.280 | 3133 | 7 |
4.290 | 4086 | 3 |
4.300 | 28516 | 17 |
4.310 | 15448 | 6 |
Last trade - 14.59pm 28/07/2025 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |
The Watchlist
P.HOTC
HotCopper
Frazer Bourchier, Director, President and CEO
Frazer Bourchier
Director, President and CEO
SPONSORED BY The Market Online